Summary
The competition between brand name and generic pharmaceutical companies is fierce. Although the Hatch Waxman Act attempted a compromise between the opposing positions of Branded pharmaceuticals and Generics, ANDA litigation and, increasingly, settlements, continue to be a major component of strategy and development on both sides. The webcast's panel stakes out these competing positions.
Topics covered include:
- Limitations on Settlement of Brand and Generic litigation
- Relationship of Authorized Generics to Settlement of brand-generic litigation
- At-risk launches in brand-generic litigation
Moderator
Martin Voet
Former Senior VP Chief IP Counsel, Allergan, Inc.
Panelists
Dominick Conde
Partner at Fitzpatrick Cella
Jay Deshmukh
Former Senior VP Global IP to Ranbaxy Labs
David Hashmall
Partner at Goodwin Procter
Steven Lee
Partner at Kenyon & Kenyon LLP
Edward W. Murray
Managing Counsel, Intellectual Property Litigation Merck & Co., Inc.
Speakers
- /en/people/h/hashmall-david
David M. Hashmall
Retired PartnerChairman Emeritus, Goodwin